ESC 2021 – finerenone’s song gets a little sweeter
Bayer’s drug shows a benefit in less severe chronic kidney disease patients in Figaro-DKD.
Bayer beefs up discovery work with Vividion buyout
Growing interest in protein degradation helps explain why Bayer had to pay $1.5bn to corner the private group.
Outlook heads to regulators with eye-friendly Avastin
But questions remain about both the Norse Two trial and the commercial opportunity.
ISTH 2021 – Blackstone’s Novartis spin-out scores
Abelacimab justifies its spin-out into the Blackstone-backed private biotech Anthos Therapeutics, and a big deal could follow.
Celldex looks beyond oncology for a resurgence
After several cancer failures Celldex tries its hand at autoimmune disease, and the market likes it.
